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Normal hematopoiesis is sustained by multipotent hematopoietic stem cells (HSCs) that are able to both self-renew and give rise to differentiated cells throughout the lifetime of an individual. These cell 
fate decisions are characterized by changes in transcriptional 
cell states, mediated by heritable epigenetic processes, notably 
posttranslational modifications of nucleosome proteins and 
direct methylation of DNA. These changes in chromatin struc-
ture are coordinated by specific “writer” and “eraser” enzymes 
and specifically bound by epigenetic “readers.” Acute myeloid 
leukemia (AML) arises as a result of dysregulation of this 
ordered transcriptional progression, resulting in an aggressive 
disease characterized by a block in differentiation and increased 
proliferation. Moreover, mutations of transcriptional regulators 
and chromatin modifiers are recurrent in AML. Importantly, the 
resultant epigenetic changes are plastic, and clinical evidence 
suggests that targeting epigenetic alterations can reset patholog-
ical transcriptional programs with clinically relevant outcomes. 
In this perspective, we will outline recent progress in the devel-
opment of agents that target chromatin in AML. We will focus 
on 3 areas: (1) targeting mutant IDH proteins; (2) therapies ini-
tially designed to target mixed-lineage leukemia (MLL)-fusions; 
and (3) targeting the transcriptional kinases CDK9 and CDK7.
Targeting DNA methylation in AML
DNA methylation plays a pivotal role in embryonic devel-
opment, cellular differentiation, and genome stability. DNA 
methylation is instigated and maintained by DNMT3A/B and 
DNMT1, respectively, and removed by TET family enzymes and 
is generally associated with transcriptional repression. However, 
while DNMT3A and TET2 are commonly mutated in AML, 
they are not yet therapeutically targetable. However, indirect 
changes in DNA methylation can occur as a consequence of 
gain-of-function mutations in the isocitrate dehydrogenase 1 
and 2 (IDH) enzymes. These neomorphic proteins generate the 
“oncometabolite” 2-hydroxyglutarate (2-HG), which interferes 
with dioxygenase enzymes, including TET, Jumonji-C histone 
lysine demethylases, and prolyl hydroxylase enzymes, result-
ing in increased DNA and histone methylation and aberrant 
transcription.
IDH mutations are present in 10%–20% of AML (Figure 1). 
As gain-of-function mutations, IDH1/2 mutations are amenable 
to small molecule inhibition, dramatically decreasing levels of 
2-HG and inducing differentiation in leukemic blasts. Clinical-
grade inhibitors of both IDH1 (ivosidenib; Tibsovo) and IDH2 
(enasidenib; Idhifa) are now US Food and Drug Administration 
approved. Early phase trials demonstrated good tolerability, 
although a specific side effect was the IDH inhibitor–associated 
differentiation syndrome, managed with corticosteroids and 
drug interruption. A phase I study of ivosidenib in relapsed/
refractory (R/R) AML reported 30%/21% CRh/CR (complete 
hematologic response/complete response) rates with a median 
duration of 8 months.1 A separate phase I/II study using ivos-
idenib upfront in older/less-fit patients reported CRh/CR rates 
of 42%/30%, respectively.2 Similar phase I/II studies of enas-
idenib showed 20% CR rates in the R/R setting3 and ORR/
CR 31%/18% (overall response rate/CR) when used upfront 
in older patients.4 The efficacy results from a phase III study 
comparing enasidenib to conventional care after failure of two 
to three lines of previous therapy have yet to be published, but 
early reports suggest a failure to meet the primary endpoint of 
overall survival (OS) benefit (IDHENTIFY NCT02577406). 
Notably, as with other “epigenetic” therapies, responses can 
take several months, highlighting the need to judge responses 
differently to conventional cytotoxic agents.5,6
Interest has therefore shifted to generating novel combina-
tion therapies, the most advanced of which takes advantage of 
preclinical synergism between IDH inhibition and azacitidine. 
Interim results from a phase II study (NCT02677922) compar-
ing upfront enasidenib +/− azacitidine has shown meaningful 
improvements in ORR (68% vs 42%) and CR (50% vs 12%) 
rates.7 A phase Ib study (NCT02677922) of upfront ivosid-
enib/azacitidine reported interim ORR/CR 78%/57%8 and 
the phase III AGILE study of ivosidenib/azacitidine is enrolling 
(NCT03173248). IDH-mutated primary AML cells are also 
more sensitive to venetoclax,9 and a phase Ib/II study of vene-
toclax/enasidenib in IDH2-mutated AML is currently ongoing 
(NCT04092179). Interim results from a phase Ib/II study of ivo-
sidenib/venetoclax +/− azacitidine (NCT03471260) in the R/R 
or nonintensive settings has demonstrated the tolerability of 
the triple-combination demonstrating overall rates of CR/CRi 
of 78% (with 50% minimal residual disease negative), with a 
median time to best response of 2 months.10
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Targeting MLL-rearranged AML
DOT1L-inhibition in MLL-mutated AML
The MLL genes encode for a family of histone methyltrans-
ferases that are essential for embryonic and adult hematopoie-
sis. The MLL1 (KMT2A) gene is recurrently mutated in AML, 
either as a result of a partial tandem duplication (PTD) or as 
part of a rearrangement, leading to the formation of fusion 
chimeric proteins with up to 70 different partners. Although 
all MLL-rearranged (MLL-r) chimeras lose their C-terminus 
methyltransferase activity, the majority fuse with translocation 
partners that are members of multi-subunit protein complexes 
involved in chromatin remodeling/transcriptional elongation, 
particularly the super elongation complex or disruptor of telo-
meric silencing 1-like (DOT1L) containing complex.
DOT1L is the only known histone H3 lysine 79 (H3K79) 
methyltransferase in mammals, where it plays an important 
role in the regulation of cell proliferation, DNA repair, and 
active transcription. Whereas DOT1L is essential for embry-
onic erythropoiesis and development, its role in adult hema-
topoiesis appears non-essential, suggesting a therapeutic 
window. DOT1L inhibition reduces H3K79 modification and 
the expression of critical MLL-r target genes, including the 
HOXA cluster and MEIS1, correlating with reduced prolif-
eration and survival (Figure  2). Intriguingly, DOT1L inhibi-
tors may also be effective in other AML genotypes driven by 
NUP98-NSD1, MLL PTD, IDH1/2, NPM1c, and DNMT3A. 
Mechanistically, DOT1L inhibition in NPM1c and DNMT3A-
mutated AML appears to involve downregulation of HOXA 
genes and MEIS1.
Pinometostat (EPZ-5676) is the most clinically-advanced 
DOT1L inhibitor. A pediatric phase I study in R/R MLL-r 
leukemias (NCT02141828) reported good tolerability, albeit 
that no objective responses were observed in this difficult 
group of patients.11 The adult phase I dose escalation study 
(NCT01684150) confirmed pinometostat as well tolerated, with 
some CRs observed, despite its pharmacokinetic limitations 
(continuous infusion up to 28 d).12 A phase Ib/II study of pinome-
tostat with azacitidine in adult MLL-r AML has now completed 
enrollment (NCT03701295) and a phase Ib/II study of pinome-
tostat alongside intensive chemotherapy upfront in MLL-r adult 
AML is ongoing (NCT03724084). New generations of orally 
available inhibitors with improved pharmacokinetics are also 
Figure 1. The role of mutant IDH proteins in AML and their therapeutic inhibition. The left “normal” panel demonstrates the standard oxidative decarbox-
ylation of isocitrate to alpha-ketoglutarate (α-KG) in the TCA cycle by the IDH1 and 2 enzymes in the cytosol and mitochondria, respectively. In the middle panel, 
mutations in IDH1 and IDH2 lead to further reduction of alpha-ketoglutarate to the oncometabolite 2HG, which inhibits the activity of α-KG-dependent dioxygenase 
enzymes, leading to increased methylation of histones and DNA, and alterations of gene expression that block differentiation and drive leukemia. In the right panel, 
the activity of mutant IDH1 and 2 enzymes is inhibited by ivosidenib and enasidenib, respectively, decreasing 2-HG and restoring the function of the dioxygenase 
enzymes, normal differentiation, and blocking the generation of leukemia programs.
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being developed, which will improve clinical utility and may 
increase responses to DOT1L-inhibition.13,14
Targeting menin
Menin, another preclinically validated MLL-r target, binds to 
the N-terminus of wild-type MLL and MLL-fusion proteins, and 
is required for aberrant gene expression. Preliminary data from 
the ongoing trial of KO-539 (KOMET-001 NCT04067336), 
which acts by disrupting the menin-MLL interaction (Figure 2), 
has shown evidence of remarkable efficacy even at low doses, with 
some patients achieving CR and reports of tumor lysis.15 This 
was associated with reduction in the expression of the key MLL 
targets HOXA/MEIS1, a fact that may account for responses in 
non-MLL-rearranged AML, including NPM1c, IDH, EZH2, 
DNMT3A, and EZH2-mutant genotypes. A phase I/II study 
of another MLL-menin inhibitor, SNDX-5613, in MLL-r and 
NPM1c AML is ongoing (AUGMENT-101 NCT04065399).
Further novel menin inhibitors are in development16,17 with 
the orally available VTP-50469 showing remarkable preclinical 
efficacy in a mouse model of Npm1c/Dnmt3a-mutant preleuke-
mia and the NPM1c-mutant OCI-AML3 human leukemia cell 
line. Mechanistically, this activity was associated with down-
regulation of MEIS1 and PBX3, although interestingly without 
disruption of HOXA gene expression.18
Histone demethylases and LSD1
Histone demethylation is also a potential target in MLL-r 
and other AML subtypes. The prototypic LSD1 an exemplar 
of the lysine specific demethylases (LSD)—one of the 2 main 
classes of histone demethylase, demethylates H3K4me1/2 and 
H3K9me1/2 histone marks—acting as both a transcriptional 
repressor or activator in a context-specific manner. LSD1 is 
part of the MLL supercomplex associated with sites of active 
transcription and LSD1 inhibition modulates H3K4me2 levels 
at genes specifically bound by the MLL-r protein. Furthermore, 
LSD inhibition increases leukemic stem cell sensitivity to 
all-trans-retinoic acid (ATRA)-mediated differentiation across 
AML genotypes, irrespective of PML-RARA status. LSD1 
inhibitors demonstrate some toxicity towards normal hemato-
poiesis, particularly erythropoiesis, although this is reversible on 
drug discontinuation, suggesting a possible therapeutic window.
Two LSD1 inhibitors, GSK2879552 (NCT02177812) and 
ORY-1001 (EudraCT 2013-002447-29), are in AML clinical tri-
als. The phase I trial of Iadademstat (ORY-1001) reported low 
toxicity, with evidence of hematological responses, especially in 
MLL-r cases.19 A phase II trial of Iadademstat + azacitidine is 
ongoing (EudraCT No.: 2018-000482-36) with encouraging 
preliminary results (ORR 73%, time to response of 36 d, lon-
gest-CR 405 d) (Salamero et al, EHA Annual Congress 2020, 
Abstract EP580).20 A further study investigating the ability of 
the LSD1 inhibitor tranylcypromine to sensitize AML to ATRA 
is also recruiting (NCT02717884).
Targeting oncogenic transcription by CDK7/9 
inhibition
Small molecule inhibitors of the cyclin-dependent kinases 
CDK7/9 have shown activity in AML. CDK9 is a key member 
Figure 2. Graphic of a prototypic MLL-fusion protein (FP). Shown are the targets of and inhibitors that block the activating program downstream of 
MLL-FP; menin inhibitors, such as SNDX-5613 and KO-539, that block the interaction of the N-terminus of the MLL-FP with menin to tether the protein at its 
target loci; inhibitors of the DOT1L H3K79 methyltransferase protein, such as pinometastat, that block H3K79methylation and transcriptional elongation; BET 
inhibitors, such as OTX015, ABBV-075, molibresib/I-BET762 and FT-1101, that block the interaction of BRD4 with acetylated histones and with it malignant 
transcription; and the CDK7 and 9 inhibitors that block phosphorylation of RNA polymerase II (RNA Pol II) and malignant transcription.
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of the P-TEFb complex that regulates transcriptional elonga-
tion, whilst CDK7 activates RNA polymerase II (RNA Pol II) by 
CDK7-dependent phosphorylation (Figure  2). Targeting these 
proteins is thought to work through reducing oncogenic over-
expression of critical leukemia-regulators such as MYC.
The CDK9 inhibitor dinaciclib inhibits MLL target genes, 
demonstrating efficacy in preclinical models of MLL-r AML.21 
Voruciclib overcomes MCL1-mediated venetoclax resistance in 
a preclinical model of AML and is undergoing phase I study 
(NCT03547115). Alvocidib has proven tolerable and shown 
encouraging responses in combination with intensive chemo-
therapy in a phase I study (NCT03298984).22 A randomized 
phase II study of alvocidib, cytarabine, and mitoxantrone versus 
cytarabine and daunorubicin (7 + 3) in newly diagnosed high-
risk AML reported higher rates of CR (70% vs 47%), but no 
improvement in OS.23
Conclusions
Hematological malignancies are characterized by mutation 
or dysregulation of epigenetic regulators. This has led to the 
development of targeted therapies aimed at eradicating malig-
nant cells through the restoration of normal epigenetic and 
transcriptional states. Epigenetic regulators represent attractive 
therapeutic targets as they often have enzymatic activities or 
binding domains amenable to small molecule inhibition, and 
the states that they govern are reversible. However, despite good 
preclinical evidence of efficacy and safety, only a few of these 
therapies have reached clinical development with encouraging 
results. It is therefore important to address the potential pitfalls 
that currently prevent us from taking full advantage of these 
rationally-designed therapies.
One obvious problem is that AML is a highly heteroge-
neous disease and that epigenetic modifiers can act as both 
tumor suppressors and oncogenes in different cellular con-
texts. Furthermore, individual patients harbor a complex clonal 
architecture that often evolves and can be selected for by treat-
ment during the course of the disease,24–26 allowing significant 
opportunity for subclonal escape or acquired resistance. Further 
understanding mechanisms of resistance will aid rational design 
of combination therapies.
In this context, clinical trials must be tailored to appropri-
ately measure clinical benefits and harms. With a large number 
of clinical-grade agents now available, it will be important to 
predict or otherwise identify genetic subgroups that respond to 
specific inhibitor classes, particularly those harboring truncal 
mutations, such as MLL-r or IDH-mutated AML. Early phase 
clinical trials inevitably test these therapies as single agents in 
highly pretreated populations, thereby decreasing the likelihood 
to observe significant benefit. Thus, promising agents might be 
discarded because of a lack of single-agent efficacy. Moreover, 
the standard response criteria used for cytotoxics are not con-
ducive to measure the likely slower response of an epigene-
tic inhibitor. In addition, as with cytotoxics, single agents are 
unlikely to eradicate such a complex disease, necessitating the 
rational development of combination therapies. In so doing, 
it will be important to anticipate and monitor for compound 
toxicities, and be mindful to either avoid the danger of inadver-
tently activating oncogenic programs or adversely affect benefi-
cial immune-mediated tumor responses.
We therefore favor expediting their use in rationally designed 
combinations with standard or other well-understood targeted 
therapies, or testing them in previously untreated patients, per-
haps those not suitable for standard therapies. Given their rela-
tive lack of cytotoxicity, trial design should anticipate prolonged 
treatment to demonstrate efficacy, consider their use as mainte-
nance therapy, and potentially develop novel outcome measures 
using rationally designed biomarkers of response.
In conclusion, facilitated by the remarkable advances in our 
knowledge of the role of dysregulated epigenetics in AML, 
translation of therapeutically targeting the epigenome in AML 
patients is ongoing. However, achieving their full clinical poten-
tial will require an even deeper understanding of the role of 
epigenetic dysregulation in malignant transformation, coupled 
with rationally designed clinical trials.
Acknowledgments
We would like to thank all the members of the Huntly laboratory 
and our funders including Cancer Research UK (C18680/A25508), 
the European Research Council (647685), MRC (MR-R009708-1), 
Blood Cancer UK, the Kay Kendall Leukaemia Fund (KKL1243), the 
Wellcome Trust (205254/Z/16/Z), the Cambridge NIHR Biomedical 
Research Centre. We apologize to those authors whose work we were 
unable to cite due to space constraints.
Disclosures
The authors have no conflicts of interest to disclose.
Sources of funding
SER is supported by a Clinician Scientist Fellowship from Cancer 
Research UK (C67279/A27957). Research in the Wellcome—MRC 
Cambridge Stem Cell Institute is funded by a grant from the Wellcome 
Trust (203151/Z/16/Z). Research in the Cancer Research UK Cambridge 
Centre is supported by a Cancer Research UK Major Centre Award 
(C9685/A25117). 
References
1. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with 
ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 
2018;378:2386–2398.
2. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep 
durable remissions in patients with newly diagnosed IDH1-mutant 
acute myeloid leukemia. Blood. 2020;135:463–471.
3. Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and 
response patterns in patients with mutant-IDH2 acute myeloid leuke-
mia treated with enasidenib. Blood. 2019;133:676–687.
4. Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of 
mutant IDH2 proteins, induces durable remissions in older patients with 
newly diagnosed acute myeloid leukemia. Leukemia. 2019;33:2575–2584.
5. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant 
IDH2 relapsed or refractory acute myeloid leukemia. Blood. 
2017;130:722–731.
6. Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute 
myeloid leukemia cell differentiation to promote clinical response. 
Blood. 2017;130:732–741.
7. DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine 
significantly improves complete remission and overall response com-
pared with azacitidine alone in patients with newly diagnosed acute 
myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) muta-
tions: interim phase II results from an ongoing, randomized study. 
Blood. 2019;134(suppl_1):643.
8. Dinardo CD, Stein AS, Stein EM, et al. Mutant IDH1 inhibitor ivo-
sidenib (IVO; AG-120) in combination with azacitidine (AZA) for 
newly diagnosed acute myeloid leukemia (ND AML). J Clin Oncol. 
2019;37(15_suppl):7011.
9. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehy-
drogenase 1 and 2 mutations induce BCL-2 dependence in acute 
myeloid leukemia. Nat Med. 2015;21:178–184.
10. Lachowiez CA, Borthakur G, Loghavi S, et al. Phase Ib/II study of 
the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor veneto-
clax +/- azacitidine in IDH1-mutated hematologic malignancies. J Clin 
Oncol. 2020;38(15_suppl):7500.
11. Shukla N, Wetmore C, O’Brien MM, et al. Final report of phase 1 study 
of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with 
relapsed or refractory MLL-r acute leukemia. Blood. 2016;128:2780.
5
  (2021) 5:6 www.hemaspherejournal.com
12. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor 
pinometostat reduces H3K79 methylation and has modest clinical 
activity in adult acute leukemia. Blood. 2018;131:2661–2669.
13. Perner F, Gadrey JY, Xiong Y, et al. Novel inhibitors of the histone 
methyltransferase DOT1L show potent antileukemic activity in 
patient-derived xenografts. Blood. 2020;136:1983–1988.
14. Weiss A, Stauffer F, Clemens C, et al. A new DOT1L inhibitor with in 
vivo activity in mouse models of MLL-translocated leukemia. Cancer 
Res. 2020;80(16 suppl):Abstract 1770.
15. Wang ES, Altman JK, Pettit K, et al. Preliminary data on a phase 1/2A 
first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in 
patients with relapsed or refractory acute myeloid leukemia. Blood. 
2020;136(suppl 1):7–8.
16. Krivtsov AV, Evans K, Gadrey JY, et al. A menin-MLL inhibitor induces 
specific chromatin changes and eradicates disease in models of MLL-
rearranged leukemia. Cancer Cell. 2019;36:660–673.e11.
17. Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 
induces remission in MLL1-rearranged and NPM1-mutated models of 
leukemia. J Clin Invest. 2020;130:981–997.
18. Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of 
preleukemia cells in a mouse model of NPM1 mutant acute myeloid 
leukemia. Science. 2020;367:586–590.
19. Salamero O, Montesinos P, Willekens C, et al. First-in-human phase 
I study of iadademstat (ORY-1001): a first-in-class lysine-specific 
histone demethylase 1A inhibitor, in relapsed or refractory acute 
myeloid leukemia. J Clin Oncol. 2020;38:4260–4273.
20. Salamero O, Somervaille T, Molero A, et al. Iadademstat shows effi-
cacy in combination with azacitidine in elderly AML patients: ALICE 
trial. HemaSphere. 2020;4(S1):245–246.
21. Baker A, Gregory GP, Verbrugge I, et al. The CDK9 inhibitor dinaciclib 
exerts potent apoptotic and antitumor effects in preclinical models of MLL-
rearranged acute myeloid leukemia. Cancer Res. 2016;76:1158–1169.
22. Zeidner JF, Lee DJ, Frattini M, et al. Phase I study of alvocidib fol-
lowed by 7 + 3 (cytarabine + daunorubicin) in newly diagnosed acute 
myeloid leukemia. Clin Cancer Res. 2021;27:60–69.
23. Zeidner JF, Foster MC, Blackford AL, et al. Final results of a random-
ized multicenter phase II study of alvocidib, cytarabine, and mitoxan-
trone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed 
high-risk acute myeloid leukemia (AML). Leuk Res. 2018;72:92–95.
24. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute 
myeloid leukaemia revealed by whole-genome sequencing. Nature. 
2012;481:506–510.
25. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of 
genetically defined subclones in acute myeloid leukemia. Cancer Cell. 
2014;25:379–392.
26. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel 
Consortium. Identification of pre-leukaemic haematopoietic stem 
cells in acute leukaemia. Nature. 2014;506:328–333.
